NURS 251 Pharmacology Module 3
Exam
UPDATED CONTENT
Portage Learning
Actual Questions & Answers with Rationales | Updated PDF
A comprehensive 90-item examination aligned with 2026-2027 Portage Learning
pharmacology course Module 3 standards. The exam assesses competence across seven
domains: pharmacokinetics and pharmacodynamics, drug administration routes and dosage
forms, dosage calculations and medication math, lifespan considerations, patient safety and
high-alert medications, patient education and cultural considerations, and
legal/ethical/regulatory foundations. Each item includes a verified answer and rationale.
Total Questions 90
Sections 7
Cognitive Levels Recall 35% / Application 45% / Analysis 20%
Question Style Scenario-Based 70% / Direct Recall 30%
Question Format Multiple Choice (4 options, one correct)
Aligned Standard 2026-2027 Portage Learning Pharmacology Curriculum
Special Features Verified Answers & Rationales | Competency Labels
Section Domain Items
Section 1 Pharmacokinetics and Pharmacodynamics Foundations Q1-Q14
Section 2 Drug Administration Routes and Dosage Forms Q15-Q28
,NURS 251 Pharmacology Module 3 | Portage Learning 2026/2027 Updated | Verified Q&A
Section 3 Dosage Calculations and Medication Math Q29-Q44
Section 4 Lifespan Considerations in Pharmacology Q45-Q58
Section 5 Patient Safety, Medication Errors, and High-Alert Medications
Q59-Q70
Section 6 Patient Education, Adherence, and Cultural ConsiderationsQ71-Q80
Section 7 Legal, Ethical, and Regulatory Foundations Q81-Q90
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated Page 2
,NURS 251 Pharmacology Module 3 | Portage Learning 2026/2027 Updated | Verified Q&A
SECTION 1: Pharmacokinetics and Pharmacodynamics Foundations
ADME, Receptors, & Therapeutic Index | Range: Q1-Q14 | Cognitive Levels: Recall 35% | Application
45% | Analysis 20% | Style: Scenario-Based 70% | Direct Recall 30%
Competency: ADME - Absorption
Q1: A patient receives an oral dose of a highly lipophilic drug. The drug is absorbed across the
GI mucosa into the bloodstream. This phase of pharmacokinetics is BEST described as:
A. Distribution - movement of drug from blood to tissues
B. Absorption - movement of drug from site of administration into systemic circulation
[CORRECT]
C. Metabolism - chemical alteration of the drug by the liver
D. Excretion - elimination of the drug from the body
Correct Answer: B
Rationale: Absorption is the movement of a drug from its site of administration into the systemic
circulation. For an oral drug, this occurs across GI mucosa. Distribution follows absorption and moves drug
to tissues. Metabolism (primarily hepatic) chemically alters the drug. Excretion (primarily renal) eliminates
the drug or its metabolites.
Competency: First-Pass Effect Application
Q2: A patient requires 20 mg of propranolol IV to achieve a therapeutic effect; the same effect
requires 80 mg orally. The MOST likely explanation is:
A. Poor GI absorption of the oral form
B. First-pass hepatic metabolism significantly reduces oral bioavailability [CORRECT]
C. Increased renal excretion of the oral form
D. Tissue redistribution of the IV form
Correct Answer: B
Rationale: The first-pass effect describes significant hepatic metabolism of orally administered drugs
before they reach systemic circulation, reducing bioavailability. Drugs given IV, sublingual, buccal, or
transdermal bypass the first-pass effect. The 4-fold dose difference (20 mg IV vs 80 mg PO) is classic for
propranolol's high hepatic extraction ratio.
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated Page 3
, NURS 251 Pharmacology Module 3 | Portage Learning 2026/2027 Updated | Verified Q&A
Competency: Distribution - Protein Binding
Q3: A patient on long-term warfarin begins taking a new medication that is highly
protein-bound. The nurse anticipates that the new drug will:
A. Increase warfarin's free (active) fraction, potentially causing toxicity [CORRECT]
B. Have no effect on warfarin activity
C. Decrease warfarin's anticoagulant effect
D. Increase warfarin metabolism
Correct Answer: A
Rationale: Warfarin is highly protein-bound (>99%) to albumin. Another highly protein-bound drug
competes for the same binding sites, displacing warfarin into the free (active) form. Increased free warfarin
increases anticoagulant effect and bleeding risk. This is a common drug-drug interaction requiring INR
monitoring and possible warfarin dose adjustment.
Competency: Metabolism - CYP450
Q4: A patient taking a substrate of CYP3A4 is prescribed ketoconazole, a potent CYP3A4
inhibitor. The nurse anticipates that the substrate drug's plasma concentration will:
A. Decrease due to enhanced metabolism
B. Increase due to inhibited metabolism, raising toxicity risk [CORRECT]
C. Remain unchanged
D. Increase due to enhanced renal excretion
Correct Answer: B
Rationale: CYP450 enzymes (especially CYP3A4) metabolize many drugs. Inhibitors (ketoconazole,
erythromycin, grapefruit juice) reduce enzyme activity, increasing substrate drug levels and toxicity risk.
Inducers (rifampin, carbamazepine, St. John's Wort) increase enzyme activity, decreasing substrate drug
levels and reducing efficacy. The nurse should monitor for toxicity and anticipate dose adjustment.
Competency: Excretion - Renal
Q5: An elderly patient with creatinine clearance 25 mL/min is prescribed a renally excreted
drug with a narrow therapeutic index. The provider is MOST likely to:
A. Increase the standard dose to overcome poor excretion
B. Decrease the dose or extend the dosing interval to prevent accumulation and toxicity
[CORRECT]
C. Administer the standard dose without monitoring
D. Switch from oral to IV route only
Correct Answer: B
Rationale: Renal excretion eliminates many drugs and active metabolites. Decreased renal function (low
CrCl) slows elimination, increasing accumulation and toxicity risk for renally cleared drugs (digoxin,
vancomycin, aminoglycosides, metformin). Dose reduction or extended intervals based on CrCl are
standard. Therapeutic drug monitoring guides further adjustment.
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated Page 4
Exam
UPDATED CONTENT
Portage Learning
Actual Questions & Answers with Rationales | Updated PDF
A comprehensive 90-item examination aligned with 2026-2027 Portage Learning
pharmacology course Module 3 standards. The exam assesses competence across seven
domains: pharmacokinetics and pharmacodynamics, drug administration routes and dosage
forms, dosage calculations and medication math, lifespan considerations, patient safety and
high-alert medications, patient education and cultural considerations, and
legal/ethical/regulatory foundations. Each item includes a verified answer and rationale.
Total Questions 90
Sections 7
Cognitive Levels Recall 35% / Application 45% / Analysis 20%
Question Style Scenario-Based 70% / Direct Recall 30%
Question Format Multiple Choice (4 options, one correct)
Aligned Standard 2026-2027 Portage Learning Pharmacology Curriculum
Special Features Verified Answers & Rationales | Competency Labels
Section Domain Items
Section 1 Pharmacokinetics and Pharmacodynamics Foundations Q1-Q14
Section 2 Drug Administration Routes and Dosage Forms Q15-Q28
,NURS 251 Pharmacology Module 3 | Portage Learning 2026/2027 Updated | Verified Q&A
Section 3 Dosage Calculations and Medication Math Q29-Q44
Section 4 Lifespan Considerations in Pharmacology Q45-Q58
Section 5 Patient Safety, Medication Errors, and High-Alert Medications
Q59-Q70
Section 6 Patient Education, Adherence, and Cultural ConsiderationsQ71-Q80
Section 7 Legal, Ethical, and Regulatory Foundations Q81-Q90
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated Page 2
,NURS 251 Pharmacology Module 3 | Portage Learning 2026/2027 Updated | Verified Q&A
SECTION 1: Pharmacokinetics and Pharmacodynamics Foundations
ADME, Receptors, & Therapeutic Index | Range: Q1-Q14 | Cognitive Levels: Recall 35% | Application
45% | Analysis 20% | Style: Scenario-Based 70% | Direct Recall 30%
Competency: ADME - Absorption
Q1: A patient receives an oral dose of a highly lipophilic drug. The drug is absorbed across the
GI mucosa into the bloodstream. This phase of pharmacokinetics is BEST described as:
A. Distribution - movement of drug from blood to tissues
B. Absorption - movement of drug from site of administration into systemic circulation
[CORRECT]
C. Metabolism - chemical alteration of the drug by the liver
D. Excretion - elimination of the drug from the body
Correct Answer: B
Rationale: Absorption is the movement of a drug from its site of administration into the systemic
circulation. For an oral drug, this occurs across GI mucosa. Distribution follows absorption and moves drug
to tissues. Metabolism (primarily hepatic) chemically alters the drug. Excretion (primarily renal) eliminates
the drug or its metabolites.
Competency: First-Pass Effect Application
Q2: A patient requires 20 mg of propranolol IV to achieve a therapeutic effect; the same effect
requires 80 mg orally. The MOST likely explanation is:
A. Poor GI absorption of the oral form
B. First-pass hepatic metabolism significantly reduces oral bioavailability [CORRECT]
C. Increased renal excretion of the oral form
D. Tissue redistribution of the IV form
Correct Answer: B
Rationale: The first-pass effect describes significant hepatic metabolism of orally administered drugs
before they reach systemic circulation, reducing bioavailability. Drugs given IV, sublingual, buccal, or
transdermal bypass the first-pass effect. The 4-fold dose difference (20 mg IV vs 80 mg PO) is classic for
propranolol's high hepatic extraction ratio.
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated Page 3
, NURS 251 Pharmacology Module 3 | Portage Learning 2026/2027 Updated | Verified Q&A
Competency: Distribution - Protein Binding
Q3: A patient on long-term warfarin begins taking a new medication that is highly
protein-bound. The nurse anticipates that the new drug will:
A. Increase warfarin's free (active) fraction, potentially causing toxicity [CORRECT]
B. Have no effect on warfarin activity
C. Decrease warfarin's anticoagulant effect
D. Increase warfarin metabolism
Correct Answer: A
Rationale: Warfarin is highly protein-bound (>99%) to albumin. Another highly protein-bound drug
competes for the same binding sites, displacing warfarin into the free (active) form. Increased free warfarin
increases anticoagulant effect and bleeding risk. This is a common drug-drug interaction requiring INR
monitoring and possible warfarin dose adjustment.
Competency: Metabolism - CYP450
Q4: A patient taking a substrate of CYP3A4 is prescribed ketoconazole, a potent CYP3A4
inhibitor. The nurse anticipates that the substrate drug's plasma concentration will:
A. Decrease due to enhanced metabolism
B. Increase due to inhibited metabolism, raising toxicity risk [CORRECT]
C. Remain unchanged
D. Increase due to enhanced renal excretion
Correct Answer: B
Rationale: CYP450 enzymes (especially CYP3A4) metabolize many drugs. Inhibitors (ketoconazole,
erythromycin, grapefruit juice) reduce enzyme activity, increasing substrate drug levels and toxicity risk.
Inducers (rifampin, carbamazepine, St. John's Wort) increase enzyme activity, decreasing substrate drug
levels and reducing efficacy. The nurse should monitor for toxicity and anticipate dose adjustment.
Competency: Excretion - Renal
Q5: An elderly patient with creatinine clearance 25 mL/min is prescribed a renally excreted
drug with a narrow therapeutic index. The provider is MOST likely to:
A. Increase the standard dose to overcome poor excretion
B. Decrease the dose or extend the dosing interval to prevent accumulation and toxicity
[CORRECT]
C. Administer the standard dose without monitoring
D. Switch from oral to IV route only
Correct Answer: B
Rationale: Renal excretion eliminates many drugs and active metabolites. Decreased renal function (low
CrCl) slows elimination, increasing accumulation and toxicity risk for renally cleared drugs (digoxin,
vancomycin, aminoglycosides, metformin). Dose reduction or extended intervals based on CrCl are
standard. Therapeutic drug monitoring guides further adjustment.
NURS 251 - Pharmacology - Module 3 - Portage Learning - 2026/2027 Updated Page 4
